Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

[Estimation of level of soluble form PECAM-1, ICAM-2 and TNF-alpha, IL-18 in serum patients with chronic myelogenic leukemia].

Authors: Kiersnowska-Rogowska, B  Izycka, A  Jablonska, E  Rogowski, F  Parfienczyk, A 
Citation: Kiersnowska-Rogowska B, etal., Przegl Lek. 2005;62(8):772-4.
Pubmed: (View Article at PubMed) PMID:16521495

The aim of this study was to estimate sPECAM-1, sICAM-2 and TNF-alpha and IL-18 concentrations in serum patients with chronic myelogenic leukemia. The results indicate of increased level sPECAM-1, sICAM-2 and TNF-alpha, IL-18 concentrations in serum patients with chronic myelogenic leukemia. Elevation levels of sPECAM-1 and sICAM-2 may lead to inhibit of making myelogenic leukemia cells infiltrations through the block of surface their receptors in patients with CML. High concentration of TNF-alpha and 11-18 in blood serum may indicate high expression of sPECAM-1 by activated specific enzymes responsible for releasing sPECAM-1.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11552593
Created: 2016-10-12
Species: All species
Last Modified: 2016-10-12
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.